Literature DB >> 31422862

Applications of CRISPR/Cas9 Technology in the Treatment of Lung Cancer.

Chunyang Jiang1, Xiaohui Lin2, Zhigang Zhao3.   

Abstract

Since its emergence, the application of CRISPR-associated nuclease 9 (Cas9) technology in cancer research has accelerated studies to investigate many aspects of treatment approaches for lung cancer, including the identification of target genes, construction of animal tumor models, and identification of drug resistance-related genes. Moreover, CRISPR/Cas9 can be used in gene therapy for lung cancer, specifically involving molecular targeted drugs and inhibitors. This article reviews the current landscape of CRISPR/Cas9 applications for lung cancer treatment as a basis for further studies. Given its promising performance, in-depth and systematic research on the application of CRISPR/Cas9 in lung cancer treatment will be necessary in future studies for its successful implementation in clinical practice.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CRISPR/Cas9; gene editing; lung cancer

Mesh:

Substances:

Year:  2019        PMID: 31422862     DOI: 10.1016/j.molmed.2019.07.007

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  8 in total

1.  Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update.

Authors:  Mayank Chaudhary; Pooja Sharma; Tapan Kumar Mukherjee
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

2.  A comprehensive map of disease networks and molecular drug discoveries for glaucoma.

Authors:  Haixin Wang; Yanhui Deng; Ling Wan; Lulin Huang
Journal:  Sci Rep       Date:  2020-06-16       Impact factor: 4.379

Review 3.  Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer.

Authors:  Markeshaw Tiruneh G/Medhin; Endeshaw Chekol Abebe; Tekeba Sisay; Nega Berhane; Tesfahun Bekele; Tadesse Asmamaw Dejenie
Journal:  Biologics       Date:  2021-05-31

4.  Evaluation on the Distribution of EGFR, KRAS and BRAF Genes and the Expression of PD-L1 in Different Types of Lung Cancer.

Authors:  Rui Zhao; Shan Gao; Haiqi He; Jia Zhang; Guangjian Zhang; Xiaopeng Wen
Journal:  Int J Gen Med       Date:  2021-09-14

Review 5.  Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer.

Authors:  Ying Liu; Xiang Ao; Wanpeng Yu; Yuan Zhang; Jianxun Wang
Journal:  Mol Ther Nucleic Acids       Date:  2021-11-19       Impact factor: 8.886

Review 6.  Multidrug-Resistant Microbial Therapy Using Antimicrobial Peptides and the CRISPR/Cas9 System.

Authors:  Yared Abate Getahun; Destaw Asfaw Ali; Bihonegn Wodajnew Taye; Yismaw Alemie Alemayehu
Journal:  Vet Med (Auckl)       Date:  2022-08-11

Review 7.  CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries.

Authors:  K Sreedurgalakshmi; R Srikar; Reena Rajkumari
Journal:  Cancer Gene Ther       Date:  2020-11-15       Impact factor: 5.987

Review 8.  The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies.

Authors:  Yogita Chhichholiya; Prabhat Suman; Sandeep Singh; Anjana Munshi
Journal:  Med Oncol       Date:  2021-07-16       Impact factor: 3.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.